Bank Of New York Mellon Corp Poseida Therapeutics, Inc. Transaction History

Bank Of New York Mellon Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$3.33 - $6.38 $162,447 - $311,235	48,783 New	48,783 $258,000
Q3 2022 Nov 14, 2022	BUY	$2.43 - $4.51 $77,541 - $143,914	31,910 Added 181.74%	49,468 $175,000
Q2 2022 Aug 15, 2022	SELL	$1.87 - $5.0 $157,998 - $422,455	-84,491 Reduced 82.79%	17,558 $45,000
Q1 2022 May 11, 2022	SELL	$3.22 - $7.04 $5,763 - $12,601	-1,790 Reduced 1.72%	102,049 $457,000
Q4 2021 Feb 11, 2022	BUY	$6.23 - $7.6 $15,269 - $18,627	2,451 Added 2.42%	103,839 $707,000
Q3 2021 Nov 12, 2021	BUY	$7.09 - $10.71 $131,079 - $198,006	18,488 Added 22.3%	101,388 $739,000
Q2 2021 Aug 11, 2021	BUY	$7.96 - $10.07 $157,608 - $199,386	19,800 Added 31.38%	82,900 $830,000
Q1 2021 May 13, 2021	BUY	$8.51 - $11.91 $285,246 - $399,211	33,519 Added 113.31%	63,100 $602,000
Q4 2020 Feb 09, 2021	BUY	$8.29 - $11.7 $52,135 - $73,581	6,289 Added 27.0%	29,581 $324,000
Q3 2020 Nov 12, 2020	BUY	$8.09 - $16.25 $188,432 - $378,495	23,292 New	23,292 $206,000

38.5M

377K

22.2K

Ticker PSTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 85,775,600
Market Cap $810M
Description
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant ...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.